A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.
World-leading Breast Cancer Oncologists Cynthia Ma MD, PhD and Massimo Cristofanilli, MD to Join Olaris Scientific and Medical Advisory Board
Share Article
Drs. Cynthia Ma and Massimo Cristofanilli to Advise on Biomarkers of Response (BoRs) to Drive Better Treatment Outcomes for Patients with Breast Cancer
I am impressed by Olaris’s technology and early data suggesting the potential use of a metabolomics signature as an independent and robust predictive biomarker in metastatic breast cancer. - Dr. Cristofanilli WALTHAM, Mass. (PRWEB) February 16, 2021 Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, has appointed Dr. Cynthia Ma of Washington University in St. Louis and Dr. Massimo Cristofanilli from Northwestern Medicine to its Scientific Advisory Board and Medic
An imaging test that measures the function of estrogen receptors in breast cancer cells can distinguish patients likely or unlikely to benefit from hormone therapy, a new study shows.
Hormone therapy is commonly given as a targeted treatment for women whose cancer cells carry receptors for estrogen. But the therapy only works for about half of all patients. Until now, there hasn’t been a good way to reliably predict who will benefit and who will not.
In a small phase 2 clinical trial, researchers showed that the cancers of all patients with working estrogen receptors remained stable or improved on hormone therapy, and progressed in all women with nonfunctional estrogen receptors.